COVID-19 | In what phase is the approval of the Sputnik V vaccine in the WHO?

The evaluation of the World Health Organization (WHO) for the emergency recognition of the Sputnik V vaccine against COVID-19 It is going in a “positive direction”, according to Russian Health Minister Mikhail Murashko.

“The process is moving forward, the work with WHO is moving in a positive direction”, Murashko emphasized to reporters.

In June, to inspect the plants where the immunizer is made and made a series of observations on the production in the company Pharmstandard-UfaVITA, mainly in relation to

In mid-September, the Deputy Chief of the Pan American Health Organization (PAHO), Jarbas Barbosa, confirmed that

The health agency restarted the analysis of Sputnik V last month and will make new visits to the plants where the vaccine is manufactured in order to gather enough evidence to include it on the list of drugs approved for emergency use.

Murashko did not specify if there are already dates organized for this and clarified that it is agreed by the developers of the inoculant and experts from the WHO, as quoted by the Sputnik news agency.

In mid-October this minister affirmed at the end of a meeting with the head of the WHO, Tedros Adhanom Gebreyesus, that for the recognition of the immunizer.

Sputnik V, developed by Gamaleya and with funding from the Russian Fund for Direct Investment, was registered in Russia in August 2020 and is one of the few drugs in the world with an efficacy greater than 90% against COVID-19.

To date, the WHO has included in the list of drugs approved for “emergency” use those of Moderna, Pfizer / BioNTech, Johnson & Johnson, and the two versions of AstraZeneca, the one made in India (called Covishield) and the one it develops in South Korea.

It also granted this authorization to those of Chinese origin from Sinovac (called CoronaVac) and Sinopharm, and more recently to Covaxin, also developed in India.

The WHO emergency use list is a prerequisite for supplying Covax, the mechanism created to and it facilitates the inclusion of the vaccine within those requested by the countries to enable international travel.

It also allows nations to accelerate their own regulatory approval to import and administer COVID-19 immunizers.

Follow us on twitter: